Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Musallam
Khaled M
KM
Taher
Ali T
AT
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality*; D016032:Randomized Controlled Trials as Topic; D055752:Small Cell Lung Carcinoma / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D013923:Thromboembolism / Q000139:chemically induced* / Q000401:mortality
D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D005047:Etoposide; D016190:Carboplatin